Brenig Therapeutics

Brenig Therapeutics is a science-based European company dedicated to pioneering breakthrough treatments for neurodegenerative diseases, focusing on developing innovative therapies and advancing the field of neurology through cutting-edge research and strategic partnerships. Its development of the LRRK2 inhibitor (BT-0267) marks a significant step forward in the company’s mission to combat neurodegenerative diseases.